NCT04464226 2026-04-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Active not recruiting
Bayer
Hoffmann-La Roche
Icahn School of Medicine at Mount Sinai
NRG Oncology
Hoffmann-La Roche
AstraZeneca
AstraZeneca
University of Alabama at Birmingham
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Australasian Gastro-Intestinal Trials Group
UNICANCER